A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2016
At a glance
- Drugs ACP 01 (Primary)
- Indications Peripheral arterial occlusive disorders
- Focus Therapeutic Use
- Sponsors Hemostemix
- 28 Jun 2016 According to a Hemostemix media release, due to the termination of the CRO (Criterium Inc) Agreement, company is placing a temporary hold on the enrollment for its phase 2 clinical trials in Canada and South Africa.
- 28 Jun 2016 Status changed from recruiting to suspended, as per Hemostemix media release.
- 16 Oct 2015 New trial record